Study summary

This was a 40-week study to investigate how safe and effective solifenacin solution was in treating children or adolescents with symptoms of overactive bladder (OAB), who completed study 905-CL-076 (NCT01565707).

Additional Study Details

Phase
3
Product
N/A
Product
Solifenacin succinate suspension
Type
Interventional
Masking
None (Open Label)
Enrollment number
148
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Plain Language Summary
Available Language(s): English

Get more information

Would you like more information about clinical trial sites that are recruiting participants for A study to investigate how safe and effective Solifenacin solution is in treating children/adolescents with symptoms of overactive bladder (OAB) who completed study 905-CL-076? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Site: 6301
    Quezon City, Philippines, 1108
    Completed
    Site: 5202
    Mexico City, Mexico, 4530
    Withdrawn
    Site: 4901
    Marburg, Germany, 35043
    Withdrawn
    Site: 3302
    Lille, France, 59037
    Withdrawn
    Site: 5504
    Campinas, Brazil, 13024-500
    Withdrawn
    Site: 3101
    Nijmegen, Netherlands, 6525 GA
    Withdrawn
    Site: 9104
    Dehradun, India, 248140
    Withdrawn
    Site: 1012
    Phoenix, AZ, United States, 85032
    Withdrawn
    Site: 1014
    Albany, NY, United States, 12208
    Withdrawn
    Site: 9109
    New Delhi, India, 110001
    Withdrawn
    Site: 9102
    Nagpur, India, 440012
    Completed
    Site: 3854
    Kharkiv, Ukraine
    Completed
    Site: 4701
    Bergen, Norway, 5021
    Withdrawn
    Site: 9004
    Kocaeli, Turkey, 41380
    Withdrawn
    Site: 4404
    London, United Kingdom, NW1 2BU
    Withdrawn
    Site: 3103
    Rotterdam, Netherlands, 3015 CE
    Completed
    Site: 4605
    Umea, Sweden, 90185
    Completed
    Site: 9002
    Izmir, Turkey, 35100
    Completed
    Site: 3209
    Antwerp, Belgium, 2650
    Withdrawn
    Site: 4702
    Trondheim, Norway, 7030
    Withdrawn
    Site: 3851
    Kyiv, Ukraine, 58001
    Withdrawn
    Site: 4604
    Stockholm, Sweden, 17176
    Completed
    Site: 4503
    Aalborg, Denmark, DK-9000
    Completed
    Site: 5205
    Mexico City, Mexico, C.P.06700
    Withdrawn
    Site: 5502
    Sao Paulo, Brazil, 05403-000
    Withdrawn
    Site: 3850
    Kiev, Ukraine, 1103
    Withdrawn
    Site: 5505
    Sao Jose do Rio Preto, Brazil, 15090-000
    Completed
    Site: 2703
    Cape Town, South Africa, 7700
    Completed
    Site: 9001
    Ankara, Turkey, 6100
    Completed
    Site: 3201
    Gent, Belgium, 9000
    Withdrawn
    Site: 3206
    Esneux, Belgium, 4130
    Withdrawn
    Site: 7003
    Saint Petersburg, Russian Federation, 194100
    Withdrawn
    Site: 9114
    Jaipur, India, 302004
    Withdrawn
    Site: 4903
    Bonn, Germany, 53105
    Withdrawn
    Site: 5503
    Porto Alegre, Brazil, 90035-003
    Withdrawn
    Site: 8201
    Seoul, Republic of Korea, 120752
    Withdrawn
    Site: 4802
    Wroclaw, Poland, 50-369
    Withdrawn
    Site: 4906
    Frankfurt, Germany, 60435
    Withdrawn
    Site: 1002
    Montreal, Canada, H3H 1P3
    Withdrawn
    Site: 2701
    Johannesburg, South Africa, 1709
    Completed
    Site: 8207
    Seoul, Republic of Korea, 110744
    Completed
    Site: 3202
    Antwerp, Belgium, 2020
    Withdrawn
    Site: 9003
    Ankara, Turkey, 6100
    Withdrawn
    Site: 3105
    Deventer, Netherlands, 7416
    Withdrawn
    Site: 9108
    Ahmedabad, India, 380007
    Completed
    Site: 4603
    Skovde, Sweden, 54185
    Withdrawn
    Site: 1005
    Hamilton, Canada, L8N 3Z5
    Completed
    Site: 3810
    Belgrade, Former Serbia and Montenegro, 11 000
    Withdrawn
    Site: 3104
    Zwolle, Netherlands, 8011 JW
    Completed
    Site: 5507
    Campinas, Brazil, 13087-567
    Withdrawn
    Site: 7002
    Moscow, Russian Federation, 123317
    Completed
    Site: 4801
    Warsaw, Poland, 04-736
    Withdrawn
    Site: 1009
    Durham, NC, United States, 27710
    Withdrawn
    Site: 4402
    Leeds, United Kingdom, LS1 3EX
    Completed
    Site: 3205
    Leuven, Belgium, 3000
    Completed
    Site: 3208
    Charleroi, Belgium, 6000
    Completed
    Site: 5506
    Curitiba, Brazil, 80240-060
    Completed
    Site: 4502
    Kolding, Denmark, 6000
    Completed
    Site: 4606
    Gothenburg, Sweden, 41685
    Completed
    Site: 4804
    Lubin, Poland, 20-093
    Withdrawn
    Site: 1008
    Tarrytown, New York, United States, 10591
    Withdrawn
    Site: 4601
    Jonkoping, Sweden, 55185
    Completed
    Site: 4504
    Koge, Denmark, 4600
    Withdrawn
    Site: 1007
    Stanford, CA, United States, 94305
    Completed
    Site: 3812
    Novi Sad, Former Serbia and Montenegro, 21000
    Withdrawn
    Site: 9005
    Istanbul, Turkey
    Withdrawn
    Site: 3811
    Belgrade, Former Serbia and Montenegro, 11 000
    Completed
    Site: 3204
    Kortrijk, Belgium, 8500
    Withdrawn
    Site: 3301
    Paris, France, 75015
    Completed
    Site: 4602
    Stockholm, Sweden, 11883
    Completed
    Site: 8203
    Daegu, Republic of Korea, 705717
    Completed
    Site: 4403
    Leeds, United Kingdom, LS1 3EX
    Completed
    Site: 1006
    Shreveport, Louisiana, United States, 71106
    Completed
    Site: 4501
    Aarhus N, Denmark, 8200
    Withdrawn
    Site: 3207
    Brussels, Belgium, 1020
    Withdrawn
    Site: 3853
    Dnipropetrovsk, Ukraine, 49100
    Completed
    Site: 3203
    Gent, Belgium, 9000
    Completed
    Site: 8206
    Incheon, Republic of Korea, 400-711
    Completed
    Site: 4803
    Gdansk, Poland, 80-952
    Withdrawn
    Site: 7005
    Moscow, Russian Federation
    Completed
    Site: 4805
    Gdansk, Poland, 80-803
    Withdrawn
    Site: 3210
    Leuven, Belgium, 3000
    Withdrawn
    Site: 1011
    Providence, Rhode Island, United States, 02906
    Withdrawn
    Site: 5203
    Leon, Mexico, 37000
    Withdrawn
    Site: 7001
    Saint Petersburg, Russian Federation, 194100
    Withdrawn
    Site: 9110
    Bangalore, India, 560017
    Withdrawn
    Site: 1015
    Cincinnati, OH, United States, 45229
    Withdrawn
    Site: 7004
    Moscow, Russian Federation, 119991
    Completed
    Site: 4401
    Sheffield, United Kingdom, S10 2TH
    Withdrawn
    Site: 5501
    Santo Andre, Brazil, 090060-650
    Completed
    Site: 1001
    Quebec, Canada, G1V 4G2
    Completed
    Site: 8202
    Seoul, Republic of Korea, 156707
    Withdrawn
    Site: 4902
    Emmendingen, Germany, 79312
    Withdrawn
    Site: 9105
    Hyderabad, India, 500018
    Withdrawn
    Site: 8204
    Gwangju, Republic of Korea, 501757
    Withdrawn
    Site: 5204
    Mexico City, Mexico, 78218

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    2

    Why are Clinical Trials Important?

    3

    Why Participate in a Clinical Trial?